CompletedPhase 2NCT00074035
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
Studying Graft versus host disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Sherif S. Farag, MD, PhD, M.DOhio State University
- Intervention
- pentostatin(drug)
- Enrollment
- 39 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2003 – 2014
Study locations (16)
- Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States
- CCOP - Christiana Care Health Services, Newark, Delaware, United States
- University of Illinois Cancer Center, Chicago, Illinois, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
- Union Hospital Cancer Program at Union Hospital, Elkton, Maryland, United States
- Mayo Clinic Cancer Center, Rochester, Minnesota, United States
- Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees Township, New Jersey, United States
- New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
- Duke Comprehensive Cancer Center, Durham, North Carolina, United States
- Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
- Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
- +1 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00074035 on ClinicalTrials.govOther trials for Graft versus host disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07166848Electrostimulation Study for Ocular Graft vs. Host DiseaseZhonghui K. Luo, MD, PhD
- RECRUITINGPHASE2NCT07246031BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell TransplantationBioPhoenix Co., Ltd.
- RECRUITINGNANCT07184853Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHDFirst Affiliated Hospital of Zhejiang University
- RECRUITINGPHASE2NCT07118254A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)Lubris Bio Pty Ltd
- RECRUITINGPHASE4NCT06824103Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host DiseaseNovartis Pharmaceuticals
- RECRUITINGPHASE3NCT07047456Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBTAnhui Provincial Hospital
- RECRUITINGPHASE2NCT06799195Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell TransplantationUniversity of Nebraska
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT07162688Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.Fujian Medical University